The US Food and Drug Administration has approved a new obesity pill called Foundayo from pharmaceutical giant Eli Lilly. This comes as good news for those who prefer oral medications over injections.
Foundayo is part of the GLP-1 class, which also includes popular weight loss drugs like Ozempic and Wegovy. These medicines mimic hormones that regulate blood sugar and digestion to make you feel fuller. Unlike its injectable competitors, Foundayo can be taken anytime without strict dietary restrictions or an empty stomach.
Initial results from clinical trials show it can help people lose a significant amount of weight over 18 months—more than double what a placebo could achieve. However, head-to-head comparisons with Wegovy are yet to be conducted. Foundayo is now available through LillyDirect, with broader distribution set for retail pharmacies and telehealth providers soon.
The quick approval from the FDA via a new expedited program highlights the growing importance of weight management pills. For Eli Lilly, this could mean more patients on their medication, potentially addressing both supply issues and patient preferences.
